Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 29 studies | 29% ± 14% | |
CD16-positive, CD56-dim natural killer cell, human | 10 studies | 30% ± 13% | |
CD16-negative, CD56-bright natural killer cell, human | 9 studies | 34% ± 14% | |
gamma-delta T cell | 7 studies | 35% ± 16% | |
mature NK T cell | 5 studies | 36% ± 17% | |
CD8-positive, alpha-beta T cell | 4 studies | 35% ± 12% |
Insufficient scRNA-seq data for expression of CD160 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 96% | 37.19 | 441 / 459 | 17% | 0.32 | 191 / 1118 |
esophagus | 93% | 49.51 | 1341 / 1445 | 20% | 0.32 | 36 / 183 |
stomach | 97% | 40.45 | 347 / 359 | 16% | 0.33 | 45 / 286 |
lung | 99% | 79.56 | 575 / 578 | 10% | 0.21 | 118 / 1155 |
uterus | 98% | 59.14 | 167 / 170 | 10% | 0.20 | 44 / 459 |
kidney | 81% | 22.63 | 72 / 89 | 25% | 0.41 | 224 / 901 |
intestine | 98% | 70.08 | 951 / 966 | 7% | 0.13 | 38 / 527 |
skin | 92% | 42.07 | 1666 / 1809 | 11% | 0.18 | 54 / 472 |
spleen | 100% | 570.35 | 241 / 241 | 0% | 0 | 0 / 0 |
bladder | 95% | 53.33 | 20 / 21 | 4% | 0.12 | 21 / 504 |
thymus | 96% | 40.76 | 624 / 653 | 4% | 0.07 | 23 / 605 |
blood vessel | 98% | 68.93 | 1313 / 1335 | 0% | 0 | 0 / 0 |
prostate | 97% | 36.70 | 238 / 245 | 1% | 0.03 | 5 / 502 |
liver | 91% | 67.73 | 206 / 226 | 4% | 0.08 | 16 / 406 |
adipose | 93% | 33.57 | 1123 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 265.07 | 859 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 86% | 20.84 | 221 / 258 | 4% | 0.06 | 10 / 230 |
ovary | 84% | 27.71 | 152 / 180 | 4% | 0.05 | 17 / 430 |
pancreas | 84% | 19.38 | 275 / 328 | 2% | 0.04 | 3 / 178 |
brain | 69% | 21.94 | 1816 / 2642 | 5% | 0.09 | 34 / 705 |
heart | 73% | 16.08 | 626 / 861 | 0% | 0 | 0 / 0 |
muscle | 45% | 8.14 | 358 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 24% | 0.51 | 7 / 29 |
tonsil | 0% | 0 | 0 / 0 | 7% | 0.17 | 3 / 45 |
eye | 0% | 0 | 0 / 0 | 3% | 0.07 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001525 | Biological process | angiogenesis |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0002385 | Biological process | mucosal immune response |
GO_0050860 | Biological process | negative regulation of T cell receptor signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0031295 | Biological process | T cell costimulation |
GO_0002729 | Biological process | positive regulation of natural killer cell cytokine production |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0002857 | Biological process | positive regulation of natural killer cell mediated immune response to tumor cell |
GO_0002250 | Biological process | adaptive immune response |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_1905675 | Biological process | negative regulation of adaptive immune memory response |
GO_2000353 | Biological process | positive regulation of endothelial cell apoptotic process |
GO_1900280 | Biological process | negative regulation of CD4-positive, alpha-beta T cell costimulation |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0098552 | Cellular component | side of membrane |
GO_0019900 | Molecular function | kinase binding |
GO_0032393 | Molecular function | MHC class I receptor activity |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0023024 | Molecular function | MHC class I protein complex binding |
GO_0032397 | Molecular function | activating MHC class I receptor activity |
GO_0032394 | Molecular function | MHC class Ib receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CD160 |
Protein name | CD160 antigen (CD160 molecule) (CD160 protein) CD160 antigen (Natural killer cell receptor BY55) (CD antigen CD160) [Cleaved into: CD160 antigen, soluble form] |
Synonyms | hCG_1762288 BY55 RP11-373C9.1-006 |
Description | FUNCTION: [CD160 antigen]: Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells . Receptor for both classical and non-classical MHC class I molecules . In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response . On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells . Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion . On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites . Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (By similarity). On activated CD4+ T cells, interacts with TNFRSF14 and down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response . In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity). .; FUNCTION: [CD160 antigen, soluble form]: The soluble GPI-cleaved form, usually released by activated lymphocytes, might play an immune regulatory role by limiting lymphocyte effector functions. . |
Accessions | ENST00000235933.10 [O95971-1] ENST00000369288.7 [O95971-1] O95971 Q6FH89 ENST00000616463.1 [O95971-4] ENST00000401557.7 [O95971-3] ENST00000584442.2 [O95971-2] |